Archive

Dive into a collection of past posts and rediscover timeless content.

FDA warning letter raises compliance risk as access push expands

Mar 12, 2026

•

1 min read

FDA warning letter raises compliance risk as access push expands

Regulators flag adverse-event reporting gaps; Novo extends WHO Foundation collaboration.

FDA warning letter hits Novo on postmarketing safety reporting

Mar 11, 2026

•

1 min read

FDA warning letter hits Novo on postmarketing safety reporting

Compliance scrutiny adds to pipeline/LOE worries as shares fall nearly 3%.

Novo partners with Hims to expand US access to Ozempic and Wegovy

Mar 10, 2026

•

1 min read

Novo partners with Hims to expand US access to Ozempic and Wegovy

Deal shifts Hims away from compounded GLP-1s; Novo drops patent suit for now.